What is Zacks Research's Forecast for Omnicell Q3 Earnings?

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Research analysts at Zacks Research boosted their Q3 2025 earnings per share (EPS) estimates for shares of Omnicell in a research note issued to investors on Tuesday, July 15th. Zacks Research analyst R. Department now expects that the company will post earnings of ($0.04) per share for the quarter, up from their prior forecast of ($0.05). The consensus estimate for Omnicell's current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell's Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.07 EPS, FY2026 earnings at $0.45 EPS, Q1 2027 earnings at ($0.01) EPS and FY2027 earnings at $0.86 EPS.

Several other analysts have also recently issued reports on the stock. Bank of America upped their target price on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Benchmark decreased their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company upped their price target on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday. Wall Street Zen upgraded shares of Omnicell from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 12th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $45.33.

Omnicell Stock Performance

NASDAQ:OMCL traded up $1.15 during trading hours on Friday, reaching $28.03. The company had a trading volume of 759,606 shares, compared to its average volume of 564,230. The company has a current ratio of 1.38, a quick ratio of 1.23 and a debt-to-equity ratio of 0.13. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.75. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of 22.22, a PEG ratio of 7.84 and a beta of 0.76. The firm's 50 day moving average price is $29.10 and its 200-day moving average price is $34.04.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. Omnicell's quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business posted $0.03 earnings per share.

Hedge Funds Weigh In On Omnicell

Several hedge funds and other institutional investors have recently modified their holdings of OMCL. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell in the fourth quarter worth $37,000. Headlands Technologies LLC bought a new stake in shares of Omnicell in the fourth quarter valued at approximately $53,000. Huntington National Bank boosted its position in shares of Omnicell by 236.4% in the fourth quarter. Huntington National Bank now owns 1,359 shares of the company's stock valued at $61,000 after acquiring an additional 955 shares during the period. GAMMA Investing LLC boosted its position in shares of Omnicell by 37.1% in the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock valued at $50,000 after acquiring an additional 458 shares during the period. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Omnicell in the fourth quarter valued at approximately $101,000. Institutional investors and hedge funds own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.